세계 애디슨병 시장 – 2023-2030

Overview
Global Addison’s Disease Market reached US$ 413.1 million in 2022 and is expected to reach US$ 644.7 million by 2030, growing with a CAGR of 4.7% during the forecast period 2023-2030.
Addison's crisis is a severe endocrine emergency immediate recognition and treatment are required. Patients diagnosed with this disease should be aware otherwise that if not recognized and treated, the adrenal crisis can be fatal. Addison's disease is caused by various factors like Autoimmune, infections, Adrenal Hemorrhage, Adrenal Hemorrhage, Infiltration and others. Mainly, Addison's disease is caused by an inability of the adrenal cortices to produce adequate adrenocortical hormones.
Furthermore, the global Addison disease market is driven by a rise in research and development, advancements in treatments and rising healthcare expenditures in the countries. Also, the rising number of clinical trials has resulted in the development of novel treatments is seeing an increase in demand from North American regions with significant competitors like Teva Pharmaceuticals, Aspen Pharma, Pfizer Inc, Merck KGaA and others actively operating in the market.
Dynamics
A Rise in the Prevalence of Addison's Disease Is Expected to Drive the Growth of The Addison's Disease Market
The rise in the prevalence of Addison’s disease is one of the key factors that drive the market to grow during the forecast period. Addison’s disease is a rare autoimmune disorder and the rise in the prevalence of this disease will increase the research and development of novel therapies which helps to boost the market.
For instance, according to an updated article published in the National Library of Medicine Addison's disease is a rare disease where the incidence is 0.6 per 100,000 of the population per year. The total number of people affected by this condition at a given time ranges from 4 to 11 per 100,000 of the population. In adults, the common age of presentation is 30 to 50 years. It is more common in women.
A Rise in Awareness of Addison's Diseases is Expected to Drive the Growth of The Addison's Disease Market
The rise in awareness of Addison's disease is the important key factor that drives the market to grow during the forecast period. General awareness about the diseases is an important key factor for every patient who is diagnosed with it for that purpose HCA Florida Healthcare initiated April is Adrenal Disease Awareness Month and HCA Florida South Tampa Hospital is raising awareness about the diagnosis and treatment of adrenal diseases.
With increased awareness, our community will become more knowledgeable about when to consult their physician regarding testing and treatment. adrenal disease awareness month is important because increased awareness emphasizes the vital purpose of the adrenal glands and encourages the general public to seek treatment if a disorder is suspected.
Need For Long-Term Treatment Will Also Expected to Drive the Growth of The Addison's Disease Market
Long-term treatment is one of the key aspects which boosts the market to grow during the forecast period. Addison's disease needs long-term steroid replacement therapy. The most widely used treatments for Addison's disease are glucocorticoid and mineralocorticoid replacement therapy. Furthermore, due to its short half-life and ability to rapidly enter into the bloodstream, hydrocortisone is one of the most popular medications in the glucocorticoid family. Furthermore, once-daily dosage regimens benefit from long-acting glucocorticoids such dexamethasone and prednisone.
Advancements in the Treatment of Addison's Disease are Expected to Drive the Growth of The Addison's Disease Market
The rise in advancements is one of the key factors that help the market to grow during the forecast period. Many emerging therapies have been invented for the treatment of Addison’s disease where cell replacement strategies are one of the technological advancements where this would be the best therapeutic alternative for patients with adrenal insufficiency. Such a strategy would go beyond the evident goal of replacing insufficient hormones and rather allow for the restoration of the HPA axis function and a possible curative strategy.
Complications Associated with Addison’s Disease Will Hamper the Market Growth
If a person is untreated with Addison's disease, a person may develop an Addisonian crisis as a result of stress on the body, such as injury, infection or illness. Typically, the adrenal glands make two or three times the usual amount of cortisol in response to physical stress. With adrenal insufficiency, not being able to increase the amount of cortisol made as a result of stress can lead to an Addisonian crisis.
An Addisonian crisis is a life-threatening situation that results in low blood pressure, low blood levels of sugar and high blood levels of potassium. It requires immediate medical care. Also, Over-treatment with fludrocortisone can cause high blood pressure (hypertension) since these complications result in the declaration of market growth during the forecast period.
Segment Analysis
The global Addison’s disease market is segmented based on type, drug class, route of administration, distribution channel and region.
The Primary Adrenal Insufficiency Segment From The Type Segment Accounted For Approximately 41.7% of Addison’s Disease Share
The primary adrenal insufficiency segment from the type segment accounted for 41.7% and it is expected to be dominated during the forecast period. Primary adrenal insufficiency is characterized by decreased aldosterone and cortisol production due to diminished gland function. It can either present acutely, which may present as an adrenal crisis, or it can be chronic, which is called Addison disease.
For instance, in February 2022, Diurnal Group plc, the speciality pharmaceutical company targeting patient needs in chronic endocrine (hormonal) diseases, announced that the first patient has been dosed in its Phase 2 European clinical trial of modified-release hydrocortisone (DNL-0200 – previously referred to as Chrono Cort for a line extension in adrenal insufficiency (AI).
Geographical Penetration
North America Accounted for Approximately 38.4% of the Market Share
North America is estimated to hold about 38.4 % of the total market share throughout the forecast period, owing to the factors such as increasing disease instances in the region, acquisition by key players, rising number of clinical trials, growing demand for new generation technologically integrated advanced therapeutic drugs for swift and long-term therapy, and a well-established healthcare infrastructure
For instance, in June 2021, Eton Pharmaceuticals, Inc, the U.S. marketer of ALKINDI SPRINKLE, a treatment for adrenocortical insufficiency in pediatric patients, announced that it has acquired U.S. and Canadian rights to Crossject’s ZENEO hydrocortisone needleless autoinjector, which is under development as a rescue treatment for adrenal crisis. ZENEO is a proprietary needleless device developed and manufactured by Crossject.
The pre-filled, single-use device propels medication through the skin in less than a tenth of a second. The device’s compact form factor, simple two-step administration, and needle-free technology make it an ideal delivery system for emergency medications that need to be administered in stressful situations by non-healthcare professionals.
Competitive Landscape
The major global players in the market include Teva Pharmaceuticals, Ralington Pharma, Aspen Pharma, Pfizer Inc, Merck KGaA, Anant Pharmaceuticals, Symbiotech, Curia, AuroPharma, Parchem fine & speciality chemicals and among others.
COVID-19 Impact Analysis
Covid 19 had a substantial impact on the global Addison’s disease market where although it is well established that intercurrent illness triggered adrenal decompensation leading to a diagnosis or worsening or primary adrenal insufficiency, this is the first description of a case in which SARS-CoV-2 infection/ COVID-19 unmasks Addison’s disease.
According to the study titled 'COVID-19 and the Endocrine System: Exploring the Unexplored' released in May 2020, the adrenal system is one of the most severely impacted organ systems in the body during acute active infection in persons with COVID-19 infection who require hospitalization. As a result of the outbreak, businesses and other non-healthcare industries were forced to close. This had an effect on Addison's disease market.
By Type
• Primary Adrenal Insufficiency
• Secondary Adrenal Insufficiency
• Tertiary Adrenal Insufficiency
By Drug Class
• Oral Corticosteroid
o Hydrocortisone
o Fludrocortisone
• Corticosteroid Injections
• Sodium Intake
By Route of Administration
• Oral
• Parenteral
By Distribution Channel
• Hospitals and Clinics
• Retail Pharmacies
• Online Pharmacies
By Region
• North America
o U.S.
o Canada
o Mexico
• Europe
o Germany
o UK
o France
o Italy
o Russia
o Rest of Europe
• South America
o Brazil
o Argentina
o Rest of South America
• Asia-Pacific
o China
o India
o Japan
o Australia
o Rest of Asia-Pacific
• Middle East and Africa
Key Developments
 In June 2022, ANI Pharmaceuticals, Inc announced that the Company received U.S. Food and Drug Administration (“FDA”) approval for the Abbreviated New Drug Application (ANDA) for Fludrocortisone Acetate Tablets USP, 0.1 mg. ANI’s Fludrocortisone Acetate Tablets are the generic version of the Reference Listed Drug (RLD) Florinef.
 In April 2022 Diurnal Group extended its distribution agreement with Er-Kim to include the distribution and marketing of Alkindi (hydrocortisone granules in capsules for opening) and Efmody (hydrocortisone modified-release hard capsule) in Greece, Cyprus and Malta.
 In January 2022, Antares Pharma announced that the United States Food and Drug Administration had granted Fast Track designation for ATRS-1902 for adrenal crisis rescue in adults and adolescents using the company's Vai novel proprietary auto-injector platform to deliver a stable liquid formulation of hydrocortisone.
Why Purchase the Report?
• To visualize the global Addison’s Disease market segmentation based on type, drug class, route of administration, distribution channel and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of global Addison’s disease market level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.
The Global Addison’s Disease market report would provide approximately 61 tables, 58 figures and 186 Pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies